Complement System as a Target for Therapies to Control Liver Regeneration/Damage in Acute Liver Failure Induced by Viral Hepatitis

Table 1

Characteristics of the study population.

Subjects	Samples	Age	Gender	ALT	AST	INR	Encephalopathy	Outcome	Diagnostic	Etiology
1	HS1	29	F	14	21	1	None	NA	Healthy	None
2	HS2	27	M	16	22	1	None	NA	Healthy	None
3	HS3	29	F	13	19	1.1	None	NA	Healthy	None
4	HS4	26	M	23	33	0.9	None	NA	Healthy	None
5	HS5	46	F	18	26	0.8	None	NA	Healthy	None
6	HS6	31	F	11	15	0.9	None	NA	Healthy	None
7	HS9	26	F	16	25	0.9	None	NA	Healthy	None
8	HS10	33	F	13	18	1.1	None	NA	Healthy	None
9	ALF1	5	F	326	331	6.7	IV	Survival	Acute liver failure	HAV
10	ALF2	14	M	877	1790	4.32	IV	Death	Acute liver failure	HAV
11	ALF3	7	M	1562	5611	2.55	III	Death	Acute liver failure	HAV
12	ALF4	14	M	313	330	8.64	IV	Death	Acute liver failure	HAV
13	ALF5	1	F	668	171	6.38	II	Death	Acute liver failure	HAV
14	ALF6	24	M	964	762	3.3	II	Death	Acute liver failure	HBV
15	ALF7	31	F	314	562	2.1	II	Survival	Acute liver failure	HBV
16	ALF8	17	M	200	120	1.7	II	Survival	Acute liver failure	HAV

Legend: HS: healthy subjects; ALF: acute liver failure patients; HAV: hepatitis A virus; HBV: hepatitis B virus; F: female; M: male; NA: not applicable.